Peter Bouwman
Overview
Explore the profile of Peter Bouwman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
3344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wijaya L, Trairatphisan P, Gabor A, Niemeijer M, Keet J, Alcala Morera A, et al.
Biochem Pharmacol
. 2021 May;
190:114591.
PMID: 33957093
Drug-induced liver injury (DILI) is the most prevalent adversity encountered in drug development and clinical settings leading to urgent needs to understand the underlying mechanisms. In this study, we have...
12.
Duijndam B, Goudriaan A, van den Hoorn T, van der Stel W, Le Devedec S, Bouwman P, et al.
Toxicol Sci
. 2021 Mar;
181(2):187-198.
PMID: 33769548
Estrogen receptor alpha (ERα) belongs to the nuclear hormone receptor family of ligand-inducible transcription factors and regulates gene networks in biological processes such as cell growth and proliferation. Disruption of...
13.
Francica P, Mutlu M, Blomen V, Oliveira C, Nowicka Z, Trenner A, et al.
Cell Rep
. 2020 Aug;
32(8):108068.
PMID: 32846126
Using genome-wide radiogenetic profiling, we functionally dissect vulnerabilities of cancer cells to ionizing radiation (IR). We identify ERCC6L2 as a major determinant of IR response, together with classical DNA damage...
14.
Bouwman P, van der Heijden I, van der Gulden H, de Bruijn R, Braspenning M, Moghadasi S, et al.
Clin Cancer Res
. 2020 Jun;
26(17):4559-4568.
PMID: 32546644
Purpose: Because is a high-risk breast/ovarian cancer susceptibility gene, sequence variants of uncertain clinical significance (VUS) complicate genetic counseling. As most VUS are rare, reliable classification based on clinical and...
15.
Monteiro A, Bouwman P, Kousholt A, Eccles D, Millot G, Masson J, et al.
J Med Genet
. 2020 Mar;
57(8):509-518.
PMID: 32152249
No abstract available.
16.
Puppe J, Opdam M, Schouten P, Jozwiak K, Lips E, Severson T, et al.
Clin Cancer Res
. 2019 May;
25(14):4351-4362.
PMID: 31036541
Purpose: BRCA1-deficient breast cancers carry a specific DNA copy-number signature ("") and are hypersensitive to DNA double-strand break (DSB) inducing compounds. Here, we explored whether (i) EZH2 is overexpressed in...
17.
Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta A, Kothari A, Wang D, et al.
Cancer Discov
. 2019 Apr;
9(6):722-737.
PMID: 31015319
Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP...
18.
Barazas M, Gasparini A, Huang Y, Kucukosmanoglu A, Annunziato S, Bouwman P, et al.
Cancer Res
. 2018 Dec;
79(3):452-460.
PMID: 30530501
The defect in homologous recombination (HR) found in BRCA1-associated cancers can be therapeutically exploited by treatment with DNA-damaging agents and PARP inhibitors. We and others previously reported that BRCA1-deficient tumors...
19.
van de Ven M, Liu X, van der Burg E, Klarenbeek S, Alexi X, Zwart W, et al.
J Pathol
. 2018 Jun;
246(1):41-53.
PMID: 29877575
Hereditary breast cancers in BRCA1 mutation carriers are mostly estrogen receptor α (ERα)-negative and progesterone receptor (PR)-negative; however, hormone depletion via bilateral oophorectomy does result in a marked reduction in...
20.
Tacconi E, Lai X, Folio C, Porru M, Zonderland G, Badie S, et al.
EMBO Mol Med
. 2017 Jul;
9(10):1398-1414.
PMID: 28729482
Maintenance of genome integrity requires the functional interplay between Fanconi anemia (FA) and homologous recombination (HR) repair pathways. Endogenous acetaldehyde, a product of cellular metabolism, is a potent source of...